A Haifa-based company has announced the promising results of a two-year study conducted in the northern Israel city. The researchers were able to significantly stop the growth of cancerous cells in female mice harboring an aggressive type of breast cancer that is difficult to treat.
All the research was done in Israel Photo Credit: Pluristem Therapeutics Inc.
Pluristem Therapeutics Inc., an Israeli placenta-based cell therapy developer, released the promising findings of a study it carried out in an article in the journal Scientific Reports on Friday. The Haifa-based researchers were able to significantly stop the growth of cancerous cells in female mice by injecting them on a weekly basis with PLacental eXpanded (PLX) cells.
The female mice were harboring human triple negative breast cancer (TNBC), an aggressive type of breast cancer that is difficult to treat. A combination of surgery, radiation therapy and chemotherapy is the current path of treatment for the disease. The breakthrough study showed that the 30 percent of the mice that were treated with the injections exhibited complete tumor remission.
“The findings of this study published in a peer-reviewed journal are the outcome of over two years of research as well as the vast knowledge of PLX cell properties we have developed over the last 10 years,” Zami Aberman, Chairman and Co-CEO of Pluristem, said. “We believe the findings show promise for the utilization of our induced PLX cells in slowing and reversing the growth of cancer cells, particularly for some cancers that don’t have viable treatment options.”
“Our unique patented manufacturing platform allows us to alter our cells’ secretion profile in correlation with the targeted cancer cells, which may open new possibilities in the field of oncology to treat solid tumors and may also offer new paths to help millions of patients around the world,” Aberman added. “As in immunotherapy technology, PLX cells potentially have the ability to communicate with the body and to secrete biological components that enhance regeneration processes and support the body in fighting cancer cells.”